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ABSTRACT 
Background: Guidelines recommendations regarding anticoagulant therapy following 
percutaneous coronary intervention (PCI) among patients with atrial fibrillation (AF) rely on 
retrospective, non-randomized observational data.  Currently patients are treated with triple 
therapy (dual antiplatelet therapy [DAPT] + oral anticoagulation therapy [OAC]) but neither the 
duration of DAPT nor the level of anticoagulation has been studied in a randomized fashion. 
Recent studies also suggest dual pathway therapy with clopidogrel plus OAC may be superior, 
and other studies suggest that novel oral anticoagulants (NOACs) such as rivaroxaban may 
further improve patient outcomes.  Design: PIONEER AF-PCI (ClinicalTrials.gov 
NCT01830543) is an exploratory, open-label, randomized, multicenter clinical study assessing 
the safety of two rivaroxaban treatment strategies and one vitamin K antagonist (VKA) treatment 
strategy in subjects who have paroxysmal, persistent, or permanent non-valvular AF and have 
undergone PCI with stent placement. Approximately 2,100 subjects will be randomized in a 
1:1:1 ratio to receive either rivaroxaban 15 mg once daily plus clopidogrel 75 mg daily for 12 
months (a WOEST trial like strategy), or rivaroxaban 2.5 mg twice daily (with stratification to a 
pre-specified duration of DAPT 1, 6, or 12 months, an ATLAS trial like strategy) or dose 
adjusted vitamin K antagonist once daily (with stratification to a pre-specified duration of DAPT 
1, 6, or 12 months, traditional triple therapy).  All patients will be followed for 12 months for the 
primary composite endpoint of TIMI major bleeding, bleeding requiring medical attention, and 
minor bleeding (collectively, clinically significant bleeding).  Conclusion: The PIONEER AF-
PCI study is the first randomized comparison of VKA vs. NOAC therapy in patients with NVAF 
receiving antiplatelet therapy following PCI to assess the relative risks of bleeding 
complications. 
Key words:  atrial fibrillation, rivaroxaban, percutaneous coronary intevention  
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Background 
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia of clinical 
significance[1], with a prevalence ranging from less than 1% among people under 60 years of 
age to approximately 10% among those over 80 years of age[2].  Over 6 million patients in 
Europe and approximately 2.3 million patients in the United States have been diagnosed with 
AF, and this number continues to grow rapidly due to the aging of the population[2].  AF is an 
independent risk factor for stroke[3], and the morbidity and mortality associated with AF-related 
stroke is more severe than that of other underlying causes[4]. 
The 2012 focused update of the ESC guidelines and 2014 AHA/ACC/HRS guidelines, 
cite antithrombotic therapy as a cornerstone in the management of AF to prevent 
thromboembolism.  Antithrombotic therapy should be carefully chosen, however, to minimize 
both the risk of ischemic stroke and the risk of bleeding.  While anticoagulation with a vitamin K 
antagonist (VKA) is recommended for moderate and high risk patients, acetylsalicylic acid 
(ASA) is recommended for AF patients at low risk for subsequent stroke[5].  Although warfarin 
is commonly used in the management of atrial fibrillation[6], its use is limited by an increased 
risk of intracranial hemorrhage and gastrointestinal bleeding [7], its interaction with food and 
other medications and [8], as well as its need for frequent monitoring.  These limitations have 
prompted the development of novel anticoagulants that can provide similar efficacy with an 
improved safety profile.   
 Among acute coronary syndrome (ACS) patients undergoing percutaneous coronary 
intervention (PCI), approximately 5 to 21% of patients have concomitant AF [9].  Despite 
overlap in the occurrence of these syndromes, the pharmacotherapies used to manage AF and 
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ACS differ. The management of AF patients who undergo stent placement for an ACS is 
challenging in so far as the risks of AF-related ischemic stroke and bleeding associated with the 
antithrombotic therapy and stent thrombosis must all be balanced.  While OAC is more effective 
than dual antiplatelet therapy (DAPT) in preventing ischemic and embolic events associated with 
AF [10], OAC with warfarin was inferior to DAPT in reducing the risk of stent thrombosis 
among ACS patients requiring first generation stent implantation [11].   
In the past, DAPT and OAC were combined in a treatment strategy labeled “triple 
therapy”.  Meta-analyses of studies involving patients with AF and coronary stents found the risk 
of major bleeding on triple therapy to be 2.2 % within the first month and 4–12 % within the first 
year on treatment [12].  The safety and effectiveness of triple therapy, however, has recently 
been challenged in the WOEST trial (What is the Optimal antiplatElet & Anticoagulant Therapy 
in Subjects With Oral Anticoagulation and Coronary StenTing) which demonstrated that the use 
of a single antiplatelet treatment (clopidogrel) in combination with an oral anticoagulant therapy 
was associated with significantly less bleeding and mortality than triple therapy[13] despite no 
increase in stent thrombosis or ischemic stroke. 
Current European guidelines regarding anticoagulant therapy following percutaneous 
coronary intervention (PCI) for ACS in patients with AF rely on limited retrospective data.  
Triple therapy consisting of a VKA, aspirin and clopidogrel is recommended for 6 months in 
patients with low or intermediate hemorrhagic risk and 4 weeks among those with higher 
bleeding risks irrespective of the type of stent.  This triple therapy regimen is followed by a 
combination of VKA and one antiplatelet therapy up to 12 months, after which lifelong treatment 
with VKA should be continued [14].  In North America, The American College of Chest 
Physician (ACCP) provided recommendations based upon 1) the risk of bleeding, 2) the 
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syndrome (ACS or stable angina) and 3) the type of stent deployed (DES vs bare metal stent 
(BMS)) [15].   
Rivaroxaban is an oral factor Xa inhibitor which is approved to reduce the risk of stroke 
and systemic embolism among patients with non-valvular atrial fibrillation (AF) by both the 
European Medicines Agency (EMA) and the United States Food and Drug Administration 
(FDA).  Rivaroxaban is also approved by the EMA to reduce the risk of cardiovascular death, 
myocardial infarction (MI) and stroke following an acute coronary syndrome among patients 
with elevated biomarkers.  The optimal dose of rivaroxaban may differ in the management of AF 
and ACS.  The administration of 15 mg and 20 mg of Rivaroxaban once daily to patients with 
non-valvular atrial fibrillation was non-inferior to dose adjusted warfarin in reducing stroke and 
systemic embolism and decreasing the risk of fatal and intracranial bleeding in the ROCKET-AF 
trial (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K 
Antagonism for Prevention of Stroke  and Embolism Trial in Atrial Fibrillation) [16].  A reduced 
dose of 15 mg daily in patients with moderate impairment of renal function (creatinine clearance 
30-49 ml/min) displayed efficacy and safety profiles similar to the overall trial results.  However, 
both 15 and 20 mg of Rivaroxaban may significantly increase bleeding if administered 
concomitantly with DAPT.  Indeed, the addition of Rivaroxaban to DAPT among ACS patients 
at daily doses > 10 mg was associated with excess bleeding including an excess risk of fatal 
bleeding relative to a total daily dose of 5 mg [17] [18].  Thus, ACS patients on DAPT may not 
be able to safely tolerate the Rivaroxaban doses administered in AF.  Among ACS patients 
treated with background therapy with DAPT, a lower dose of rivaroxaban, 2.5 mg twice daily, 
however, was associated with a reduction in cardiovascular death, myocardial infarction (MI), 
and stroke (ATLAS ACS 2-TIMI 51) compared to DAPT alone [18].  While safe and effective in 
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ACS patients, this lower 2.5 mg BID dose of rivaroxaban administered with DAPT has not been 
evaluated in patients with AF for the prevention of stroke or systemic embolism. 
This manuscript describes the design of the PIONEER AF-PCI Trial (An OPen-label, 
Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of 
Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects 
With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention) (ClinicalTrials.gov 
NCT01830543), an open-label, randomized, multicenter trial assessing the safety of an “ATLAS 
2 like” low dose rivaroxaban plus DAPT strategy versus a “WOEST like” rivaroxaban plus 
single thienopyridiene strategy versus a traditional “triple therapy strategy” (OAC plus DAPT) 
following PCI with stent placement in patients with paroxysmal, persistent, or permanent non-
valvular AF.Based on the exploratory study design and a relatively small sample size, the study 
proceeds with the null hypothesis that bleeding rates will be similar across these three strategies. 
In order to be considered clinically meaningful, any observed between-group differences will 
have to be sufficiently large.   
 
Study operations 
The trial is funded by Johnson and Johnson and Bayer. The authors, members of the 
Executive Steering Committee, are responsible for the design and conduct of the study, the 
drafting and editing of this paper, as well as the analysis and reporting of the final results.  The 
executive committee consists of members of the academic leadership of the trial and members 
from each sponsoring company.  The executive committee appointed an independent Data 
Monitoring Committee (DMC) Chair, identified the DMC members, created the DMC charter 
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and receives recommendations from the DMC regarding the safety of participants, the scientific 
integrity of the study, possible additional analysis or modifications to the trial. 
 
Study objectives 
The primary objective of the PIONEER AF-PCI study is to assess the safety of two 
rivaroxaban treatment strategies as compared to the current standard of care (a dose-adjusted 
VKA treatment strategy) in subjects with paroxysmal, persistent, or permanent non-valvular AF 
undergoing PCI with stent placement, based on the composite of Thrombolysis in Myocardial 
Infarction (TIMI) major bleeding, minor bleeding, and bleeding requiring medical attention 
events (known collectively as clinically significant bleeding) during 12 months of therapy. 
 
Study population and patient selection 
Approximately 2,100 men and women at least 18 years of age who have 
electrocardiographically documented paroxysmal, persistent, or permanent non-valvular AF 
(defined as AF not considered to be caused by a primary valve stenosis) and have undergone a 
PCI procedure (with stent placement) are being enrolled. 
The principal inclusion and exclusion criteria a provided in the on line supplement Table 
I, and include conditions that contraindicate OAC or confer an unacceptable risk of bleeding, a 
history of stroke or transient ischemic attack (TIA) or hemodynamic or cardiac electrical 
instability. The INR must be <2.5 at the time of randomization.  Eligible subjects must provide 
written informed consent prior to randomization in the study as well as informed consent to 
collect their vital status at the end of scheduled follow-up, 12 months after entry in order to 
minimize missing data.  
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Randomization and treatment protocol 
Randomization in equal proportion to 1 of 3 treatment strategies is stratified by the intended 
duration of DAPT (1, 6, or 12 months) and balanced by randomly permuted blocks (Figure 1): 
  “Arm 1” Rivaroxaban 15 mg once-daily treatment strategy (12 months) (WOEST- 
Like Strategy):  Rivaroxaban 15 mg (or 10 mg for subjects with moderate renal impairment 
[creatinine clearance (CrCl): 30 to 50 ml/min]) once daily plus background single antiplatelet 
therapy with clopidogrel 75 mg (or alternate P2Y12 inhibitor) daily for 12 months.  Therapy with 
low-dose ASA should be withheld following randomization; however, at the discretion of the 
investigator, ASA may be continued for up to 24 hours before the first dose of study drug.  
 “Arm 2” Rivaroxaban 2.5 mg twice-daily treatment strategy (pre-specified duration 
of DAPT 1, 6, or 12 months)(ATLAS 2-Like Strategy): Rivaroxaban 2.5 mg twice daily plus 
background DAPT with low-dose ASA (75 mg to 100 mg per day) plus clopidogrel 75 mg (or 
alternate P2Y12 inhibitor) daily for prespecified duration of 1, 6 or 12 months followed by 
rivaroxaban 15 mg (or 10 mg for subjects with moderate renal impairment) once daily plus 
background single antiplatelet therapy with low-dose (75-100 mg) of ASA. 
 “Arm 3” VKA treatment strategy (pre-specified duration of DAPT of 1, 6, or 12 
months) (Triple Therapy Strategy): Dose-adjusted VKA once daily (target INR 2.0 to 3.0), or 
as directed by the investigator, plus background DAPT for the length of intended DAPT.  At the 
end of the intended duration of 1 or 6 months, subjects will remain on a dose-adjusted VKA once 
daily (target INR 2.0 to 3.0) plus background single antiplatelet therapy with low-dose (75-100 
mg) ASA. 
Subjects are randomly assigned a treatment strategy by an interactive voice/web response 
system on Day 1.  The investigator must pre-specify the intended duration of DAPT (1, 6, or 12 
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months) and the intended use of an alternate P2Y12 inhibitor (prasurgrel or ticagrelor) instead of 
clopidogrel before randomization. Randomization must occur after the INR is 2.5 or below 
within 72 hours following sheath removal, and may be performed while the subject is in the 
hospital or at the study site if after hospital discharge.  
Subjects will be administered the first dose of study drug (rivaroxaban or VKA) according to 
the timing specified for each of the treatment strategy groups, and no sooner than 2 hours after 
the final dose of bivalirudin, 4 hours after the final dose of intravenous unfractionated heparin, 
eptifibatide, or tirofiban, 12 hours after the final dose of other intravenous or subcutaneous 
anticoagulants, dabigatran or apixaban, or 24 hours after the final dose of abciximab, 
fondapariunx, or non-study rivaroxaban.  If at any time during DAPT the investigator determines 
that clopidogrel (or alternate P2Y12 inhibitor) should be permanently discontinued earlier than 
the intended DAPT duration (1, 6, or 12 months; as pre-specified before randomization) due to 
the subject's clinical status, the subject will be transitioned to the single antiplatelet therapy phase 
with low-dose aspirin (75-100 mg) while maintaining the randomized OAC treatment strategy 
(i.e., rivaroxaban, 15 mg daily for those in Arm  2, or VKA for those in Arm 3). For those 
subjects in Arm 1 for whom antiplatelet therapy must be discontinued, they will continue with 
rivaroxaban 15mg daily alone for the remained of the study.  All study drugs are administered 
orally. 
For patients randomized to the triple therapy (TT) strategy (Arm 3), careful attention is 
given to maintaining anticoagulation intensity in the targeted INR (international normalized 
ratio) of 2.0 to 3.0. Compliance with all other assigned therapies will be assessed by pill counts. 
The study consists of a screening phase, a 12-month open label treatment phase, and an end 
of treatment/early withdrawal visit.  The total duration of participation in the study for each 
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subject is approximately 12 months.  Subjects will return to the study center for multiple 
scheduled visits.  Additional unscheduled telephone calls and visits by the subject to the site are 
permissible for management of therapy, to enhance treatment compliance or for evaluation of 
adverse events.  Subjects must permanently discontinue study drug if they have an MI, ischemic 
stroke, intracranial bleeding, or bleeding into a critical organ, including intraocular bleeding.  If a 
subject permanently discontinues study drug or withdraws before the end of the open-label 
treatment phase, he or she will have an early withdrawal/end-of-treatment visit assessment no 
more than 7 days after the last dose of study drug.  During the early withdrawal visit or the end-
of-treatment visit at 12 Month, investigators must ensure that all subjects initiate therapeutic 
anticoagulation based upon protocol-specified instructions during transitions between 
rivaroxaban and VKA or another anticoagulant according to standard practice.   
 
Primary and secondary safety endpoints 
The primary safety endpoint is the percentage of subjects experiencing either TIMI major 
bleeding, minor bleeding, or bleeding requiring medical attention events (known collectively as 
clinically significant bleeding) by the end of 12 months of randomized therapy, assessed 
according to intention-to-treat for all patients receiving at least one dose of the randomized study 
medications.  Secondary safety endpoints include the incidence of each component of the TIMI 
clinically significant bleeding composite (TIMI major bleeding, minor bleeding, and bleeding 
requiring medical attention), the composite of adverse cardiovascular events (cardiovascular 
death, MI, and stroke), as well as cardiovascular death, MI, stroke, and stent thrombosis.  
 
Safety outcomes and definitions 
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Safety evaluations performed throughout the study include monitoring of clinical events 
(cardiovascular death, MI, stroke, bleeding events, and stent thrombosis), adverse events, and 
performing clinical laboratory tests.  Investigators will be required only to classify bleeding 
events by the TIMI scale.  An independent Clinical Endpoints Committee (CEC) assesses 
bleeding events according to the TIMI scale and alternative scales, including clinically 
insignificant bleeding events to the extent these are documented. The TIMI scale effectively 
accounts for large or catastrophic bleeding events, but places less emphasis on declining 
hemoglobin levels or transfusions of small volumes of blood products that occur commonly in 
patients undergoing PCI. The CEAC will therefore also assess bleeding using the International 
Society on Thrombosis and Hemostasis (ISTH) classification, which designates major bleeding 
events, clinically relevant non-major bleeding, and minimal bleeding events. A third bleeding 
assessment schema, the BARC (Bleeding Academic Research Consortium) scale, defines 5 
degrees of bleeding, including none, bleeding that is not actionable and does require additional 
evaluation, hospitalization or treatment by a healthcare professional, any overt, actionable 
hemorrhage, clinical, laboratory, and/or imaging evidence of bleeding with specific healthcare 
provider responses, bleeding related to myocardial revascularization surgery, and fatal bleeding 
events. Finally, the GUSTO scale categorizes bleeding as severe, moderate or mild. 
In order to account for transfusion, hemoglobin measurements will be adjusted for any 
packed red blood cells or whole blood transfused between the pre-bleeding and post-bleeding 
hemoglobin measurements.  The number of units of packed red blood cells and whole blood 
combined will be added to the change in hemoglobin. If only a hematocrit value is known, the 
corresponding hemoglobin value will be assumed to be one third of the hematocrit value (in 
g/dL).   
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Other adverse events of special interest include any bleeding event that does not meet 
serious adverse event criteria and any event occurring within 30 days before a permanent 
discontinuation. 
 
Exploratory secondary analyses 
Blood samples for pharmacokinetic and pharmacodynamic analyses will be collected 
from 120 subjects at selected participating sites. 
 
Statistical considerations 
This is an open-label, randomized controlled multicenter study; the study team will 
remain blinded to treatment information until database lock.  All reported bleeding events will be 
adjudicated, and analyses of the primary safety endpoint and other bleeding endpoints will be 
based on adjudicated events. The primary safety endpoint is the percent of subjects developing 
the composite of TIMI major bleeding, minor bleeding, and bleeding requiring medical attention 
(clinically significant bleeding) over the course of the 12month randomized treatment period.   
PIONEER is an exploratory trial designed to generate hypotheses of interest with a sample size 
that is calculated based on showing the minimum number of subjects needed to detect a 
difference of >6% in the incidence between two groups at 80% statistical power with a 2-sided 
alpha of 0.05.  Assuming a 16% incidence of clinically significant bleeding with the VKA 
treatment strategy, a sample size of 700 subjects per treatment strategy group (total study sample 
size of 2,100 across 3 treatment strategy groups) will have about 80% power to detect a >6% 
difference in incidence rates between any 1 of the 2 rivaroxaban treatment strategy groups 
against the VKA treatment strategy group.   
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Analysis data sets 
Two analysis sets are to be used: the intent-to-treat (ITT) analysis set and the safety 
analysis set.  All primary analyses in the trial will be based on the safety analysis set, which 
consists of all randomized subjects who receive at least 1 dose of study drug.  The intent-to-treat 
(ITT) analysis set includes all randomized subjects.  Subjects will be analyzed in the treatment 
groups on an “as randomized” basis.  The safety analysis set includes all ITT subjects who 
received at least one dose of study medication. 
Methods of analysis 
The primary safety analysis will describe percentages of cumulative treatment-emergent 
endpoint events observed from the time of the first study drug administration up to 2 days 
following discontinuation of the study drug.  The primary analysis will be based on pooled data 
across all strata within each randomized treatment strategy group.  The time from administration 
of the first dose of study drug to the first occurrence of the primary safety endpoint event, major 
bleeding, will be analyzed using a Cox proportional hazard model with treatment strategy group 
as a covariate, stratified by intended DAPT period, to provide a point estimate and 2-sided 95% 
CI for the treatment effect of relative risk reduction (RRR) (RRR=100 x [1 – hazard ratio]%).  
Cumulative event rates over time will be summarized using the Kaplan-Meier method.  
Sensitivity analyses to assess the robustness of the time to event analysis described above will 
include an unstratified log-rank test and an analysis that includes all post-randomization events 
(including those that occur after 2 days of discontinuation of the last study drug).  Table 1 and 2 
summarize the analysis methods for the primary and secondary safety endpoint respectively. 
Interim analysis 
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Two formal interim reviews of the safety data will be performed by the DMC when 
approximately 10% and 50% of subjects have completed at least one month of the allocated 
treatment.  The data review will include adverse events (specifically, clinically significant 
bleeding, adverse cardiovascular events, stent thrombosis), dosing information, 
completion/withdrawal information, demographic and baseline characteristics, labs, and 
treatment assignment information.  The following summaries will be provided for the interim 
analyses: summaries of the frequency of observed INR measurements after randomization and 
time in therapeutic range (TTR) which is the percentage of INR values in target ranges from 2 to 
3 and from 1.8 to 3.2, based on imputed INR values.  A closer examination may be warranted for 
the subjects taking Riva 10 mg, as they may have renal impairment.  There is no formal stopping 
rule for either success or futility pre-specified for these interim safety data analyses since this 
study is exploratory in nature.  The interim analyses are designed to help the DSMB with 
adequate level of safety data monitoring support, and are not meant for testing any interim 
hypotheses.  Besides, the trial sample size is not adequate for testing any safety endpoints at the 
interim basis. The primary focus in this trial remains on collecting evidence on key safety 
endpoints at the end of proposed 12 month follow up. 
Conclusion 
The PIONEER AF-PCI exploratory trial evaluates the safety of three treatment strategies 
among a broad group of patients with paroxysmal, persistent, or permanent non-valvular AF 
following PCI with stenting.  The trial provides an assessment of the safety of rivaroxaban when 
added to current guidelines based medical therapy for AF. 
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Figure 1: Study design of PIONEER AF-PCI 
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Table 1: Summary of Primary Endpoint Analysis Methods 
Endpoint Analysis Period Analysis Set Method  
Primary Safety Endpoint Treatment-emergent period 
(primary) 
 
Post-randomization period 
(supportive) 
Safety Analysis Set Two-sample proportion 
 
Cox-model (HR, 95% CI) 
 
Kaplan-Meier 
 
Table 2:  Summary of Secondary Endpoint Analysis Methods 
Endpoint Analysis Period Analysis Set Method 
Components of primary 
safety endpoint 
(TIMI Major, TIMI Minor, 
Bleeding Requiring 
Medical Attention 
Treatment-emergent 
period 
 
 
Safety Analysis Set 
 
2-sample proportion 
 
When appropriate,  
Cox-Model (HR, 95% CI) 
         Kaplan-Meier 
Composite of adverse 
cardiovascular events 
 
  
Treatment-emergent 
period 
 
 
Safety Analysis Set 
 
2-sample proportion 
 
When appropriate, 
Cox-Model (HR, 95% CI) 
        Kaplan-Meier 
Components of adverse 
cardiovascular events (MI, 
Stroke, CV Death)+ Stent 
thrombosis 
  
Treatment-emergent 
period 
 
 
Safety Analysis Set 
 
2-sample proportion 
 
When appropriate,  
Cox-Model (HR, 95% CI) 
         Kaplan-Meier  
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